Related Experiment Video
Updated: Jun 20, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Retinoids, methotrexate and cyclosporine
Current Problems in Dermatology
|August 28, 2009
Summary
Acitretin offers effective long-term psoriasis maintenance but carries teratogenicity risks. Methotrexate is a safe, efficient option for severe cases, while cyclosporine serves as a potent short-term emergency treatment.
Area of Science:
- Dermatology
- Pharmacology
Background:
- Psoriasis is a chronic inflammatory skin condition requiring effective systemic treatments.
- Current treatment options include retinoids, methotrexate, and cyclosporine, each with specific efficacy and safety profiles.
Purpose of the Study:
- To review the efficacy and safety of acitretin, methotrexate, and cyclosporine for psoriasis management.
- To provide guidance on optimal dosing, monitoring, and patient selection for these systemic therapies.
Main Methods:
- Review of existing literature on acitretin, methotrexate, and cyclosporine in psoriasis treatment.
- Analysis of efficacy data (e.g., PASI 90) and safety profiles, including side effects and long-term toxicity.
- Evaluation of treatment guidelines and recommendations for monitoring and dose adjustments.
Main Results:
- Acitretin is effective for maintenance (40% PASI 90) but teratogenic; low-dose initiation and gradual increase are recommended. Methotrexate is a safe, efficient first-line treatment for severe psoriasis, with rare liver toxicity concerns managed by non-invasive tests.
- Cyclosporine is an effective emergency treatment, particularly for young patients, but requires careful kidney function monitoring due to potential long-term toxicity; it is safe in pregnancy.
Conclusions:
- Acitretin, methotrexate, and cyclosporine are valuable systemic treatments for psoriasis, each with distinct indications and management strategies.
- Careful patient selection, appropriate dosing, and vigilant monitoring are crucial for optimizing efficacy and minimizing risks associated with these therapies.
- Updated guidelines are needed to reflect current understanding and best practices for systemic psoriasis treatment.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:27Acne Infection
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.